Impacts of Pharmacokinetic Gene Polymorphisms on Steady‐State Plasma Concentrations of Simvastatin in Thai Population
Clinical and Translational Science · 2025-05 · 18 (5)
DOI: 10.1111/cts.70225 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 29.04.2025. Verfasst von Sayanit Tipnoppanon und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Ph.D. Program in Clinical Biochemistry and Molecular Medicine, Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn…. Hauptthemen laut MEDLINE: Simvastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Polymorphism, Single Nucleotide, Coronary Artery Disease. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Thailand Science research and Innovation Fund, Chulalongkorn University, The Special Task Force for Activating Research (STAR), Rachadapisek Somphot Fund, Chulalongkorn University, The 100th Anniversary Chulalongkorn University Fund for Doctoral Scholarships from the Graduate School, Chulalongkorn University.
Abstract (Originalsprache)
Simvastatin, an HMG‐CoA reductase inhibitor, is widely used for hypercholesterolemia but may cause myotoxicity linked to its plasma concentration. Pharmacokinetic gene polymorphisms influence inter‐individual variability in simvastatin exposure. This study investigated the effects of pharmacokinetic gene polymorphisms on steady‐state simvastatin plasma levels in Thai patients. Eighty‐nine Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment for at least 2 weeks without dose adjustment were recruited from King Chulalongkorn Memorial Hospital. Simvastatin lactone and acid concentrations were measured 12 h post‐dose using UHPLC–MS/MS. Pharmacokinetic gene polymorphisms, including ABCB1, ABCC2, ABCG2, SLCO1B1, SLCO1B3, CYP3A4, and CYP3A5 , were genotyped by MassARRAY System. The results showed that patients with the SLCO1B1 c.521TC+CC genotype had significantly higher simvastatin acid levels than those with c.521TT (0.53 vs. 0.19 ng/mL, p = 0.03). Similarly, the SLCO1B1 * 1b/ * 15 genotype was associated with higher simvastatin acid levels than SLCO1B1 * 1a /* 1a (0.58 vs. 0.16 ng/mL, p < 0.001). These findings suggest that SLCO1B1 c.521T>C, alone or with c.388A>G ( SLCO1B1 * 1b/ * 15 ), reduces OATP1B1 function, leading to elevated simvastatin acid levels and increased myotoxicity risk. This study confirms the association of SLCO1B1 rs4149056 (c.521T>C) with higher simvastatin plasma levels in Thai patients. The study highlights the potential role of SLCO1B1 genotyping, particularly rs4149056 (c.521T>C) and rs2306283 (c.388A>G), in guiding statin therapy for Thai patients, which could help optimize treatment and reduce adverse effects such as statin‐induced myotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Ph.D. Program in Clinical Biochemistry and Molecular Medicine, Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand.
- Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR), Chulalongkorn University, Bangkok, Thailand.
- Division of Ambulatory and Hospital Medicine, Department of Medicine, King Chulalongkorn Memorial Hospital, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Chula Clinical Research Center (ChulaCRC), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, Thailand.
ORCID-Profile: Sayanit Tipnoppanon, Pajaree Chariyavilaskul, Thanate Srimatimanon, Monpat Chamnanphon, Natchaya Vanwong
Förderung
- Thailand Science research and Innovation Fund, Chulalongkorn University
- The Special Task Force for Activating Research (STAR), Rachadapisek Somphot Fund, Chulalongkorn University
- The 100th Anniversary Chulalongkorn University Fund for Doctoral Scholarships from the Graduate School, Chulalongkorn University
- Society of Transnational Academic Researchers Scholars Network
Zitieren
APA
Tipnoppanon, S., Udomnilobol, U., Siwamogsatham, S., Vorasettakarnkij, Y., Sukasem, C., Prueksaritanont, T., Chariyavilaskul, P., Yodsurang, V., Srimatimanon, T., Chamnanphon, M., & Vanwong, N. (2025). Impacts of Pharmacokinetic Gene Polymorphisms on Steady‐State Plasma Concentrations of Simvastatin in Thai Population. Clinical and Translational Science, 18(5). https://doi.org/10.1111/cts.70225
Vancouver
Tipnoppanon S, Udomnilobol U, Siwamogsatham S, Vorasettakarnkij Y, Sukasem C, Prueksaritanont T, et al. Impacts of Pharmacokinetic Gene Polymorphisms on Steady‐State Plasma Concentrations of Simvastatin in Thai Population. Clinical and Translational Science. 2025;18(5). doi:10.1111/cts.70225
BibTeX
@article{Tipnoppanon2025,
author = {Tipnoppanon, Sayanit and Udomnilobol, Udomsak and Siwamogsatham, Sarawut and Vorasettakarnkij, Yongkasem and Sukasem, Chonlaphat and Prueksaritanont, Thomayant and Chariyavilaskul, Pajaree and Yodsurang, Varalee and Srimatimanon, Thanate and Chamnanphon, Monpat and Vanwong, Natchaya},
title = {Impacts of Pharmacokinetic Gene Polymorphisms on Steady‐State Plasma Concentrations of Simvastatin in Thai Population},
journal = {Clinical and Translational Science},
year = {2025},
volume = {18},
number = {5},
doi = {10.1111/cts.70225}
}
EUVIMED